Deerfield Management Company, L.P. (Series C) Orchard Therapeutics PLC Transaction History

Deerfield Management Company, L.P. (Series C)

$4.84 Billion
Q1 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.36 - $0.49 $1.36 Million - $1.86 Million	-3,787,709 Reduced 54.5%	3,161,707 $1.17 Million
Q3 2020 Nov 16, 2020	SELL	$4.11 - $6.45 $1.28 Million - $2 Million	-310,572 Reduced 4.28%	6,949,416 $28.6 Million
Q2 2020 Aug 14, 2020	SELL	$5.75 - $11.99 $9.21 Million - $19.2 Million	-1,602,259 Reduced 18.08%	7,259,988 $43.6 Million
Q4 2019 Feb 14, 2020	SELL	$10.15 - $15.58 $622,732 - $955,879	-61,353 Reduced 0.69%	8,862,247 $122 Million
Q2 2019 Aug 14, 2019	BUY	$13.2 - $20.63 $11.9 Million - $18.6 Million	900,000 Added 11.22%	8,923,600 $125 Million

Q4 2018 Feb 14, 2019	BUY	$12.4 - $18.7 $99.5 Million - $150 Million	8,023,600 New	8,023,600 $126 Million

Others Institutions Holding ORTX

# of Institutions

Shares Held

545K

Call Options Held

Put Options Held

View Full List

About Orchard Therapeutics plc

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

More about ORTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account